Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 243 participants.

Also called NCT04507061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 243 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04507061
  • EudraCT 2019-003297-53
Other papers using this trial's data
  • The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2025-05-30 DOI, PubMed 39656628, PMC12123308 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Belgium, Bulgaria, Denmark, Finland, Germany, Israel, Italy, Poland, Slovakia, Spain, Sweden, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04507061. Randomized; quadruple masking; primary purpose treatment. Start 2020-09-01 (actual); primary completion 2022-03-08 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.
Acronym
CONCORD
Intervention (Drug)
runcaciguat
Intervention (Other)
Placebo
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct04507061
Content hash
be272ecd8e8d41b54cb0412955bd24672118a109423e8710e8c184e471cb757a